Skip to content

We See A
World of Vibrant
Possibilities

Learn More

We See
New Ways to
Healthier Vision

Learn More

We See the
Brilliance of
Science

Learn More

We Are Graybug
We See You

Learn More
“We believe that no patient should have to settle for good enough. We are curious and focused on finding practical solutions that make a real difference.”
Fred Guerard, PharmD, CEO
Who We Are
“Our passion is to help people with vision-threatening diseases live fuller, more vibrant lives through healthier vision. That’s why we come to work every day.”
Fred Guerard, PharmD, CEO
Who We Are
“The power of science means nothing until you see the impact it can have on people’s lives. Our work starts with listening to the people we serve the ophthalmologists and their patients.”
Parisa Zamiri, MD, CMO
Who We Are
“Our singular focus is to deliver transformative medicines for the treatment of chronic diseases of the retina and optic nerve, and we do it in partnership with them.”
Parisa Zamiri, MD, CMO
Who We Are
10 Years of
Vibrant Vision

Since 2011, we have been dedicated to transformative science making healthy vision more accessible and manageable for patients with chronic vision-threatening eye diseases. Watch the video to learn about how it all started, what drives us, and what our vision for the future looks like.

Join Us
Join Us
Vision Loss
Approximately 80 million Americans are affected by potentially blinding eye disease and this number is projected to double by 2030 based on an aging population and the increasing prevalence of diseases that can cause vision loss, such as wet AMD, diabetic retinopathy, including diabetic macular edema, and glaucoma.
0
 MIL
AMERICANS SUFFERING VISION LOSS
Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly worldwide. Approximately 170 million people worldwide and 11 million people in the United States suffer from age-related macular degeneration, of which 10 to 15% – about 25 million worldwide and 1.5 million in the United States – have active blood vessel growth and leakage, or wet AMD.
0
 MIL
AMD US
0
 MIL
AMD WORLDWIDE
Diabetic Retinopathy and Diabetic Macular Edema
With diabetes on the rise, diabetic retinopathy (DR) and diabetic macular edema (DME) are leading causes of acquired vision loss in the young and middle-age adult population. More than 90 million people worldwide and about 10 million in the United States suffer from DR of which 20 million worldwide and 1.5 million in the United States have DME.
0
 MIL
DR US
0
 MIL
DR WORLDWIDE
Glaucoma
Glaucoma is one of the most common ophthalmic disorders characterized by the progressive degeneration of the optic nerve that leads to visual impairment. It affects approximately 76 million people worldwide, of which approximately 2.7 million live in the United States. Primary Open Angle Glaucoma (POAG) is the most common type of glaucoma.
0
 MIL
GLAUCOMA US
0
 MIL
GLAUCOMA WORLDWIDE
Vision loss is one of the worst fears of an aging population.
Vibrant Vision

Sight is our most precious sense. At Graybug Vision, we believe that the world should be a place of brilliance, clarity, light and hope. We See You!

What We Solve for

For people with chronic diseases of the retina and the optic nerve, we develop medicines that make healthy vision more accessible and manageable, promoting better compliance and visual outcomes.

Learn More

What We Solve for

“What we experience in everyday practice are patients failing to return for their regular injections or coming back when the disease has already caused irreversible damage to their retina. Some patients will even drop out of treatment completely. Graybug’s science may be able to address this unmet need.”

David Boyer, MD
Retina-Vitreous Associates Medical Group Adjunct Clinical Professor at University of Southern California/Keck School of Medicine

Learn More

What We Solve for

“I’m excited about Graybug’s technology which is designed for the sustained delivery of pharmacologic agents to the eye. It has the potential to improve real world outcomes of patients with retinal diseases by reducing their treatment burden.”

Arshad Khanani, MD
Director of Clinical Research, Sierra Eye Associates
Clinical Associate Professor at the University of Nevada, Reno School of Medicine

Learn More
Our Proprietary Technologies
We are singularly focused on developing medical solutions that deliver longer-lasting and improved outcomes for chronic vision-threatening diseases, enabled through our proprietary technologies. They are designed to allow sustained delivery of pharmacologic agents to the eye in a well-tolerated and controlled manner with the goal to achieve extended duration of effectiveness.
Learn More
Learn More

Our Pipeline

Based on our proprietary technologies, our R&D pipeline targets a range of chronic vision-threatening diseases, such as wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, as well as primary open angle glaucoma.

GB-401

GB-401 is designed to be a twice-per-year intravitreal beta-blocker for the treatment of primary open angle glaucoma (POAG).

Learn More

GB-102

GB-102 is designed to be a twice-per-year intravitreal pan-VEGF inhibitor for the treatment of wet age-related macular degeneration (wet AMD).

Learn More

GB-103

GB-103 is designed to be a once-per-year intravitreal pan-VEGF inhibitor for the treatment of diabetic retinopathy (DR).

Learn More
GB-401
GB-102
GB-103

We Are Graybug

We are a clinical stage biopharmaceutical company founded in 2011 on the basis of technology licensed from the Johns Hopkins School of Medicine. We are focused on developing transformative medicines that help people with chronic vision-threatening diseases of the retina and the optic nerve.

Learn More
Graybug Vision Laboratory Baltimore, MD
Connect with Us
Sign up for ongoing news and events.